March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

This meeting marks the sixth Annual US Japan Workshop on Cancer Biomarkers. Presentations by Japanese colleagues will be organized throughout the 3 days for better integration. We want to foster an environment of collaboration between EDRN-NCI and Japan Agency for Medical Research and Development (AMED) funded investigators. Presentations by EDRN investigators will provide NCI Program Staff with updates on progress made by individual researchers and by the EDRN as a collaborative network.

Monday, March 18, 2019

7:00 a.m. – 8:00 a.m. <i>Pre Function Area</i>	Sign-in and Continental Breakfast
8:00 a.m. – 8:05 a.m. <i>Grand Ballroom</i>	Opening of Steering Committee Meeting and Approval of September 2018 EDRN Steering Committee Meeting Minutes Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute
8:05 a.m 8:10 a.m.	Welcome Scott Hiebert, Ph.D., Vanderbilt-Ingram Cancer Center
8:10 a.m 8:25 a.m.	 Charge to Participants: Strategic Priorities EDRN - Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute AMED - Tetsuo Noda, M.D., Ph.D., Cancer Institute, Japanese Foundation for Cancer Research, Director
8:25 a.m. – 9:15 a.m. <i>Grand Ballroom</i>	Session 1: Personalized Medicine in Companion Diagnostics Chair : Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
8:35 a.m. – 8:45 a.m.	Development of Circular RNAs as Cancer Biomarkers Arul Chinnaiyan, M.D., Ph.D., University of Michigan
8:45 a.m. – 8:50 a.m.	Q&A

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Monday, March 18, 2019 (Continued)

Session 1: Personalized Medicine in Companion Diagnostics (Continued)

8:50 a.m. – 9:10 a.m. Grand Ballroom	Analysis of Immunological Resistance to Anti- tumor Immunity Yoshihiro Ohue, M.D., Ph.D., Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Laboratory Head
9:10 a.m. – 9:15 a.m.	Q&A
9:15 a.m. – 10:05 a.m. <i>Grand Ballroom</i>	Session 2: Genotype, Next Gen Sequencing, and Genomics Chair : Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
9:15 a.m. – 9:35 a.m.	The Integrative Genomics of Early Prostate Cancer Paul Boutros, Ph.D., M.B.A., University of California Los Angeles
9:35 a.m. – 9:40 a.m.	Q&A
9:40 a.m. – 10:00 a.m.	Progression of Hepatocellular Carcinoma: from Early to Advanced Cancer Hiroyuki Aburatani, M.D., Ph.D., The University of Tokyo, Research Center for Advanced Science and Technology, Professor
10:00 a.m. – 10:05 a.m.	Q&A
10:05 a.m 10:25 a.m.	Break
10:25 a.m. – 12:30 p.m. <i>Grand Ballroom</i>	Session 3: Novel Technologies toward Developing Cancer Biomarkers Chair: Paul Wagner, Ph.D., National Cancer

Institute

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Monday, March 18, 2019 (Continued)

Session 3: Novel Technologies toward Developing Cancer Biomarkers (Continued)

10:25 a.m. – 10:45 a.m. Grand Ballroom	N-NOSE:1st Screening Technology for Cancer Using Nematode Olfaction Yohei Matsunaga, Ph.D., Hirotsu Bio Science, Inc., Head Research Fellow
10:45 a.m. – 10:50 a.m.	Q&A
10:50 a.m. – 11:10 a.m.	AI (Deep Learning) Cancer Diagnosis with Small Amount of Blood Nobuyuki Ota, Ph.D., Preferred Medicine, Inc., Chief Executive Officer
11:10 a.m. – 11:15 a.m.	Q&A
11:15 a.m. – 11:35 a.m.	Using Machine-learning Assisted Histopathology (HistoMAP) to Enable Early Detection of Aggressive Prostate Cancer Andries Zijlstra, Ph.D., Vanderbilt University Medical Center
11:35 a.m. – 11:40 a.m.	Q&A
11:40 a.m. – 12:00 p.m.	Measurement and Inference of Contextual Biomarkers Ruedi Aebersold, Ph.D., Institute of Molecular Systems Biology, ETH Zurich
12:00 p.m. – 12:05 [p.m.	Q&A
12:05 p.m. – 12:25 p.m.	Improving Early Detection of Breast Cancer with Auto-anti-glycoprotein Antibodies Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute
12:25 p.m. – 12:30 p.m.	Q&A

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Monday, March 18, 2019 (Continued)

12:30 p.m. – 2:00 p.m.	Lunch (On Your Own)
12:30 p.m. – 2:00 p.m. Skyline Junior Ballroom	EDRN Executive Committee Meeting with Larry Norton, M.D., Chair of Network Consulting Team (Closed Session)
2:00 p.m. – 5:15 p.m. <i>Grand Ballroom</i>	Session 4: Progress on Biomarkers for Selected Cancers Chair: Paul Wagner, Ph.D., National Cancer Institute
2:00 p.m. – 2:20 p.m.	Potential Usefulness of ApoA2 Isoforms for the Screening and Risk Stratification of Pancreatic Cancer Kazufumi Honda, D.D.S., Ph.D., Department of Biomarkers for Cancer Early Detection, National Cancer Center Research Institute, Laboratory Head
2:20 p.m. – 2:25 p.m.	Q&A
2:25 p.m. – 2:45 p.m.	TBD Wade Iams, M.D., Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
2:45 p.m. – 2:50 p.m.	Q&A
2:50 p.m. – 3:10 p.m.	The High Specificity Secondary Screening Biomarker for Prostate Cancer "PSA G-Index" Koji Ueda, Ph.D., Japanese Foundation for Cancer Research, Cancer Precision Medicine Center, Project Leader
3:10 p.m. – 3:15 p.m.	Q&A

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Monday, March 18, 2019 (Continued)

Session 4: Progress on Biomarkers for Selected Cancers (Continued)

3:15 p.m. – 3:35 p.m. Grand Ballroom	Blood Protein Biomarkers for Early Detection of Pancreatic Cancers Sumio Ohtsuki, Ph.D., Kumamoto University, Faculty of Life Sciences, Department of Pharmaceutical Microbiology, Professor
3:35 p.m. – 3:40 p.m.	Q&A
3:40 p.m 4:00 p.m.	Break
4:00 p.m. – 4:20 p.m.	<u>Colorectal/Esophageal Cancer</u> Robert Schoen, M.D., M.P.H., University of Pittsburgh
4:20 p.m. – 4:25 p.m.	Q&A
4:25 p.m. – 4:45 p.m.	<u>Pancreatic Cancer</u> Samir Hanash, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
4:45 p.m. – 4:50 p.m.	Q&A
4:50 p.m. – 5:10 p.m.	Breast Cancer Karen Anderson, M.D., Ph.D., Arizona State University/The Biodesign Institute
5:10 p.m. – 5:15 p.m.	Q&A
5:15 p.m. – 5:45 p.m. <i>Grand Ballroom</i>	 Panel Discussion of Issues Raised During Previous Sessions Moderators Tetsuo Noda, M.D., Ph.D., Cancer Institute,

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Monday, March 18, 2019 (Continued)

5:45 p.m. Adjourn for the Day

5:45 p.m. - 6:30 p.m. Executive Session (Closed)
Skyline Junior Ballroom AMED, EDRN Program Staff and

EDRN Leadership

Tuesday, March 19, 2019

7:00 a.m. – 8:00 a.m. Sign-in and Continental Breakfast

Pre Function Area

8:00 a.m. - 8:30 a.m. State of the EDRN

Grand Ballroom Sudhir Srivastava, Ph.D., M.P.H., National Cancer

Institute

8:30 a.m. - 9:20 a.m. Session 5: Guest Lectures

Grand Ballroom Chair: Paul Wagner, Ph.D., National Cancer

Institute

8:30 a.m. – 8:50 a.m. Integration of Multi-omics Data to Identify

Biomarkers for Cancer Risk

Wei Zheng, M.D., Ph.D., Vanderbilt-Ingram Cancer

Center

8:50 a.m. – 8:55 a.m. Q&A

8:55 a.m. – 9:15 a.m. Drug Target Discovery by Proteomics

Tesshi Yamada, M.D., Ph.D., National Cancer Center Research Institute, AMED Japan Cancer

Research Project, Program Officer

9:15 a.m. – 9:20 a.m. Q&A

9:20 a.m. - 10:35 a.m. Session 6: Biospecimen Science: Collection,

Grand Ballroom Availability and Accessibility

Chair: Paul Wagner, Ph.D., National Cancer

Institute

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Tuesday, March 19, 2019 (Continued)

11:10 a.m. – 11:15 a.m.

Session 6: Biospecimen Science: Collection, Availability and Accessibility (Continued)

	(
9:20 a.m. – 9:40 a.m. Grand Ballroom	Integration of Clinical Data and Repeated Imaging Measures for the Early Detection of Lung Cancer Yuankai Huo, Ph.D., Vanderbilt University Medical Center
9:40 a.m. – 9:45 a.m.	Q&A
9:45 a.m. – 10:05 a.m.	Development of the Collaborative Research and Biobanks and Biobanking Network in Japan Tohru Masui, M.D., Ph.D., Keio University School of Medicine, AMED Genomic Medicine R&D Platform Utilization System, Program Officer
10:05 a.m. – 10:10 a.m.	Q&A
10:10 a.m. – 10:30 a.m.	<u>Use Right Samples to Answer Right Questions-</u> <u>Lessons and Strategies</u> Ziding Feng, Ph.D., Fred Hutchinson Research Cancer Center
10:30 a.m. – 10:35 a.m.	Q&A
10:35 a.m 10:55 a.m.	Break
10:55 a.m. – 12:35 p.m. <i>Grand Ballroom</i>	Session 7: Update on Current Projects Chair : Paul Wagner, Ph.D., National Cancer Institute
10:55 a.m. – 11:10 a.m.	Development of Combinatorial Biomarker(s) for Pancreatic Cancer Diagnosis and Prognosis Sukhwinder Kaur, Ph.D., University of Nebraska Medical Center

Q&A

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Tuesday, March 19, 2019 (Continued)

Session 7: Update on Current Projects (Continued)

11:15 a.m. – 11:30 a.m. Grand Ballroom	Quantitative Image Analyses for Breast Cancer <u>Diagnosis and Risk Prediction</u> John Heine, Ph.D., H. Lee Moffitt Cancer Center and Research Institute, Inc.
11:30 a.m. – 11:35 a.m.	Q&A
11:35 a.m. – 11:50 a.m.	Combining Biomarkers to Improve Early Lung Cancer Diagnosis Eric Grogan, M.D., M.P.H., Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
11:50 a.m. – 11:55 a.m.	Q&A
11:55 a.m. – 12:10 p.m.	Urine-derived Biomarkers from a Racially Diverse Cohort of Men Biopsied for Prostate Cancer Indu Kohaar, Ph.D., Center for Prostate Disease Research, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center
12:10 p.m. – 12:15 p.m.	Q&A
12:15 a.m. – 12:30 p.m.	Biomarkers for Ovarian Cancer Detection Steven Skates, Ph.D., Massachusetts General Hospital
12:30 a.m. – 12:35 p.m.	Q&A
12:35 p.m 2:00 p.m.	Lunch (On Your Own)

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Tuesday, March 19, 2019 (Continued)

12:35 p.m. – 2:00 p.m. Skyline Junior Ballroom

2019 EDRN Scientific Workshop Organizing Committee Meeting

Chair: Arul Chinnaiyan, M.D., Ph.D., University of Michigan

- Anirban Maitra, M.B.B.S., The University of Texas MD Anderson Cancer Center (by Phone)
- o Matthew Schabath, Ph.D., H. Lee Moffitt Cancer Center and Research Institute, Inc.
- o Marc Lenburg, Ph.D., Boston University
- o Robert Schoen, M.D., M.P.H., University of Pittsburgh
- o Amanda Paulovich, M.D., Ph.D., Fred Hutchinson Research Cancer Center
- o NCI Program Staff

2:00 p.m. – 5:40 p.m. *Grand Ballroom*

Session 8: Developing Deliverables and Regulatory Requirements (4 Concurrent Breakout Sessions)

Session Questions:

- 1. What differentiates EDRN in this area from other programs nationally or internationally?
- 2. What are the most exciting things that will happen in biomarker cancer research over the next five years? Why so few biomarkers to validate?
- 3. Is EDRN well positioned to lead in these areas?
- 4. What is/are the biggest challenges EDRN faces to maintain or take on leadership in those areas?
- 5. If given unlimited resources, how would you/your group go about making the single biggest impact in early detection?
- 6. What models of collaboration will EDRN need to undertake to early detection cancer research and its delivery to the population?

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Tuesday, March 19, 2019 (Continued)

5:40 p.m.

Session 8: Developing Delivera	ables and Regulatory Requirements
(C	Continued)

	(Continuou)
2:00 p.m. – 3:30 p.m. <i>Gulch</i>	 Table 1: Investing in Fundamental Discovery <u>Discussion Facilitators/Reporters</u>: Karen Anderson, M.D., Ph.D., Arizona State University/The Biodesign Institute James Herman, M.D., University of Pittsburgh Cancer Institute
2:00 p.m. – 3:30 p.m. Skyline Junior Ballroom	 Table 2: Leading the Science of Validation <u>Discussion Facilitators/Reporters</u>: Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Steven Skates, Ph.D., Massachusetts General Hospital
2:00 p.m. – 3:30 p.m. SOBRO	 Table 3: Enabling Screening Strategies <u>Discussion Facilitators/Reporters</u>: Martin Sanda, M.D., Emory University Ziding Feng, Ph.D., Fred Hutchinson Cancer Research Center
2:00 p.m. – 3:30 p.m. <i>12-South</i>	 Table 4: Moving Discoveries to Diagnostic Tests <u>Discussion Facilitators/Reporters</u>: Arul Chinnaiyan, M.D., Ph.D., University of Michigan Daniel Chan, Ph.D., Johns Hopkins University
3:30 p.m. – 3:50 p.m.	Break
3:50 p.m. – 5:40 p.m. <i>Grand Ballroom</i>	Reports from Session 8 Discussions (5-minute report plus 10-minute discussion for each group)

Adjourn for the Day

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Wednesday March 20, 2019

7:00 a.m. – 8:00 a.m. Sign-in and Continental Breakfast Pre Function Area

8:00 a.m. - 12:00 p.m. Collaborative Group Meetings (By Invitation Only)

12-South Breast and Gynecological Cancers

 Steven Skates, Ph.D., Massachusetts General Hospital

o Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

o Christos Patriotis, Ph.D., National Cancer Institute

o Sharmistha Ghosh-Janjigian, Ph.D., National

Cancer Institute

Gulch Gastrointestinal Cancers

o Brian Haab, Ph.D., Van Andel Research Institute

o Robert Schoen, M.D., M.P.H., University of

Pittsburgh

o Matthew Young, Ph.D., National Cancer Institute

Skyline Junior Ballroom Lung and Upper Aerodigestive Cancers

o Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

o James Herman, M.D., University of Pittsburgh

Cancer Institute

o Lynn Sorbara, Ph.D., National Cancer Institute

o Karl Krueger, Ph.D., National Cancer Institute

SOBRO Prostate and Urological Cancers

o O. John Semmes, Ph.D., Eastern Virginia Medical

School

o Martin Sanda, M.D., Emory University

o Jacob Kagan, Ph.D., M.Sc., National Cancer

Institute

12:00 p.m. - 1:00 p.m. Lunch (On Your Own)

March 18-20, 2019 Hilton Garden Inn, Downtown Nashville, Tennessee

Wednesday, March 20, 2019 (Continued)

1:00 p.m. – 2:00 p.m. <i>Grand Ballroom</i>	Reports from Collaborative Groups
1:00 p.m. – 1:15 p.m.	 Breast and Gynecological Cancers Steven Skates, Ph.D., Massachusetts General Hospital Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center
1:15 p.m. – 1:30 p.m.	 Gastrointestinal Cancers o Brian Haab, Ph.D., Van Andel Research Institute o Robert Schoen, M.D., M.P.H., University of Pittsburgh
1:30 p.m. – 1:45 p.m.	 Lung and Upper Aerodigestive Cancers Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center James Herman, M.D., University of Pittsburgh Cancer Institute
1:45 p.m. – 2:00 p.m.	 Prostate and Urological Cancers O. John Semmes, Ph.D., Eastern Virginia Medical School Martin Sanda, M.D., Emory University
2:00 p.m. – 2:10 p.m.	 Final Remarks Joshua LaBaer, M.D., Ph.D., Arizona State University/The Biodesign Institute Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
2:10 p.m.	Adjourn